Immuron Ltd — Major Shareholding Notification 2009

Sep 8, 2009

==> picture [193 x 41] intentionally omitted <==

==> picture [145 x 83] intentionally omitted <==

9 September 2009

The Manager The Company Announcement Office Australian Stock Exchange Limited Sydney NSW

Dear Sir Completion of Transfer of Oral Immunotherapy Patent to Immuron Limited.

Attached is the joint news release that will be made in Australia and Israel today. The release relates to the completion of the above transaction and Hadasit Medical Research Services & Development Limited becoming a major shareholder in Immuron Limited.

Yours faithfully

==> picture [217 x 128] intentionally omitted <==

Graeme Stevens Company Secretary Immuron Limited

1

Joint News Release

9 September 2009

MELBOURNE, Australia and JERUSALEM, Israel.

Completion of Transfer of Oral Immunotherapy Patent to Immuron.

Hadasit becomes Major Shareholder.

Immuron and Hadasit are pleased to announce the completion of the acquisition of intellectual property (IP) by Immuron from Hadasit in the area of oral immuntherapies, and the establishment of Hadasit as the largest shareholder in Immuron, with a 19.99% stake. The initial applications of the technology platform associated with this IP will be type 2 diabetes, liver cancer (hepatoma), and hepatitis C.

Clinical trials are expected to start within the next 3 months

Hadasit is the technology transfer arm of Hadassah University Medical Centre which is the largest clinical research centre in Israel. It has a global reputation for excellent medical and scientific research.

Professor Yaron Ilan and his team at Hadassah have developed the concept of treating autoimmune and chronic diseases with orally delivered polyclonal antibodies, and Professor Yaron Ilan of Hadassah will serve as Immuron’s Medical Director. Immuron is a Melbourne based biopharmaceutical company with a commercialised technology platform for manufacturing bulk polyclonal antibodies that are suitable for oral delivery.

Professor Colin Chapman, Executive Chairman of Immuron said, “I welcome the involvement of such a distinguished and capable institution in Immuron’s research and development activities. The joint effort, which is now possible, is capable of turning the concept of oral immunotherapy into a series of “proof of concept” trials. From there it should only be a short journey to commercialisation if the trials are successful”.

Dr Einat Zisman, CEO of Hadasit said “We are very pleased that our collaboration with Immuron has reached this stage. The combined efforts of Hadassah’s IP and Immuron capabilities can yield a new approach to address serious diseases and metabolic syndromes".

About Immuron

Immuron Limited (IMC.ASX IMROY OTCQX :) is a biopharmaceutical company focused on oral immunotherapy using dairy-derived health products. Immuron’s antigen-primed antibody manufacturing technology enables it to rapidly develop polyclonal antibody and other protein-based oral therapies to a range of important infectious and immune- mediated diseases, including metabolic syndrome, influenza, cancer therapy-related GI tract Mucositis, and HIV/AIDS related immune activation.

About Hadasit

Hadasit (www.hadasit.co.il), the technology transfer company of Hadassah MC, was established to promote and commercialize Hadassah's continuously generated intellectual property, aimed at finding solutions to problems faced by modern medicine. Hadassah-generated intellectual property has already received global acclaim in the international medical research arena with its cutting-edge biomedical technology for the development of novel therapeutics, diagnostic methods and devices.

Hadasit’s obligation to the actualization of its projects is rooted in its belief that medical knowledge can make a difference only when it is translated into medical practice. Hadasit is committed to advancing medicine worldwide by creating value from intellectual property, not simply for commercial value, but for the sake of humankind.

Hadasit’s ultimate responsibility is to guide technologies from innovation to commercial application. To accomplish this, Hadasit is equipped with the fullspectrum of resources and capabilities required for composing and conducting the ‘symphony’ of pre-clinical services and clinical studies, establishing start-up companies, offering product licensing and providing international consulting services.

For additional information or to schedule an interview with Hadasit CEO Dr. Einat Zisman, please contact Yael Bosem-Levy, Hadassah Spokesperson, 97250-4048666, yael@hadassah.org.il

About Hadassah University Medical Center JERUSALEM, ISRAEL

� Since 1912, Hadassah has set the standard and created much of the infrastructure for national health care in the pre- State of Israel, and since the establishment of the State of Israel.

� Welcomes every individual who requires medical attention without regard for race, religion, gender, ethnicity or political persuasion -- and has done so since its inception.

� The Hadassah University Medical Center includes two university hospital campuses in Jerusalem: Hadassah–Ein Kerem, a 850-bed tertiary care referral center and Hadassah-Mt. Scopus, a 350-bed community hospital. Together, they incorporate all medical and surgical sub-specialties, treating more than one million people annually.

• The largest employer in Jerusalem excluding the government: 850

• physicians 1,940 nurses, 1,020 paramedical and support staff; two campuses with more than 1,000 beds, 31 operating theatres, 9 intensive care units and over 120 outpatient clinics. Committed to excellence in health care, medical research and medical education.

� Conducting more than half the hospital research in Israel, Hadassah physicians have pioneered innovative and unique medical treatments, introducing them to Israel and many areas of the world. Their clinical and

research achievements have of gained fame throughout the world, garnering Hadassah an international reputation for excellence.

� Hadasit, Hadassah's Technology Transfer Company, promotes and commercializes the intellectual property and R&D capabilities continuously generated by Hadassah physicians and scientists. Hadasit’s successful enterprising of Hadassah’s biomedical technology – including novel therapeutics, diagnostics and devices – has gained Hadassah global recognition

� Partners with the Hebrew University in five medical academic institutions: the Schools of Medicine; Nursing; Dental Medicine; Occupational Therapy; Public Health and Community Medicine.

• Founded, owned and supported by Hadassah, the Women's Zionist Organization of America (HWZOA), the largest women's, largest Jewish and largest volunteer organization in the United States, with 300,000 members in more than 1,000 chapters. HWZOA also initiated and maintains educational institutions, child rescue services and youth programs throughout the State of Israel.

Hadassah International coordinates the activities of Hadassah Units in more than 20 countries all over the world.

� A member of the American Hospital Association

Nominated for the 2005 Nobel Peace Prize for its ongoing initiatives to use medicine as a Bridge to Peace, Hadassah conducts a wide variety of training programs for medical personnel and students from the Palestinian Authority, Egypt and Jordan as well as 90 countries throughout the world.

Hadassah as a “Bridge to Peace”

For many years Hadassah has been providing medical services to Palestinians who live in the West Bank and Gaza Strip. In addition, Hadassah has been involved in numerous cooperative programs with Arab physicians, various Palestinian hospitals and medical personnel in the Palestinian Authority. Hadassah collaborates with a number of NGOs on special projects to improve the level of medical services for patients in general, and Palestinian patients in particular.

Since 1960, Hadassah has trained over 800 students from more than 90 countries culminating in a Master of Public Health Degree; has helped more than one million Africans retain their eyesight, while training local doctors to continue fighting eye disease; has brought healing to orphans with AIDS in Ethiopia and trained Ethiopian physicians and nurses; brought critical care expertise to earthquake-torn Armenia, Turkey, and Greece and to tsunami victims in South East Asia; and has assisted in the recovery effort at the bombed U.S. Embassies in Nairobi and Tanzania.